Emmes, a United States-based full-service Clinical Research Organisation, announced on Monday1, that it has named Dr Paul VanVeldhuisen as the president of Emmes Public Sector.
Dr VanVeldhuisen has more than 25 years of experience in clinical research. He joined Emmes in 1993 and later became a principal investigator. He has held roles of increasing responsibility in the company. Dr VanVeldhuisen has a PhD in epidemiology from The George Washington University, an MS in biostatistics from the University of Washington and a BS in mathematics from Calvin University.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business